ArticleJournal of clinical practice and research2026
Reduced Levels of Resolvin D1 and Thrombospondin-1 in Vernal Keratoconjunctivitis.
Article in Journal of clinical practice and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare serum levels of resolvin D1 (RvD1) and thrombospondin-1 (TSP-1) between patients with vernal keratoconjunctivitis (VKC) and healthy controls and to investigate their potential relevance to disease pathogenesis. Materials and Methods: A total of 72 individuals were enrolled in this case-control study, including 36 subjects diagnosed with VKC and 36 healthy counterparts matched for age and gender. Serum RvD1 and TSP-1 levels were measured using ELISA. Age and gender distributions were analyzed to ensure group comparability. Results: No significant differences were observed between the groups in age (VKC: 10.31±4.43 years; controls: 10.66±3.90 years; p=0.724) or gender (15 females and 21 males in each group; p=1.00). Serum TSP-1 levels were significantly lower in the VKC group [60.68 (50.60-78.01) ng/mL] compared with controls [73.49 (64.40-90.67) ng/mL; p=0.011]. Similarly, RvD1 levels were significantly decreased in patients with VKC [67.80 (63.79-68.63) ng/mL] compared with controls [69.85 (65.38-85.60) ng/mL; p=0.009]. ROC curve analysis showed an AUC of 0.681 for RvD1 (sensitivity: 94.4%, specificity: 51.4%) and 0.677 for TSP-1 (sensitivity: 63.9%, specificity: 77.1%). Conclusion: Reduced serum levels of RvD1 and TSP-1 in patients with VKC suggest disruption of inflammatory resolution and immune regulation. These biomarkers may play a role in VKC pathogenesis and offer potential diagnostic or therapeutic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.